Glucose ( DrugBank: Glucose )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	3
86	肺動脈性肺高血圧症	2
88	慢性血栓塞栓性肺高血圧症	1

49. 全身性エリテマトーデス

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800015030	2018-03-01	2018-03-01	A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus	The Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE	Systemic Lupus Erythematosus	Case series:add-on or replace dapagliflozin;	Dept. Rheumatology, Renji Hospital South Campus	NULL	Pending	18	70	Both	Case series:35;	4 (Phase 4 study)	China
2	NCT03296995 (ClinicalTrials.gov)	July 1, 2017	25/9/2017	Accuracy, Feasibility and Acceptance of CGM Lupus	Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Systemic Lupus Erythematosus	Systemic Lupus Erythematosus;Critical Illness;Diabetic Blood Glucose Monitoring	Device: Flash glucose monitoring system	RenJi Hospital	NULL	Recruiting	18 Years	N/A	All	30	N/A	China
3	NCT00029926 (ClinicalTrials.gov)	January 2002	26/1/2002	Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity	A Pilot Study of F-18FDG Positron Emission Tomography (PET) to Assess the Distribution of Activated Lymphocytes in Systemic Lupus Erythematosus (SLE)	Lupus Erythematosus;Systemic	Drug: 2-deoxy-2 [F-18] fluoro-2-d-glucose	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	20	N/A	United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01953965 (ClinicalTrials.gov)	September 2013	26/9/2013	Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance	Brigham and Women's Hospital	University of Pennsylvania;University of Maryland;Yale University	Terminated	18 Years	72 Years	Both	4	Phase 2	United States
2	NCT01637675 (ClinicalTrials.gov)	May 2013	1/7/2012	Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension	Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension	Pulmonary Hypertension;Pulmonary Arterial Hypertension;Cardiovascular Diseases;Lung Diseases;Tanshinone IIA Sulfonate	Drug: 20 mg sildenafil citrate by mouth;Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth	The First Affiliated Hospital of Guangzhou Medical University	Jiangsu Carefree Pharmaceutical Co., LTD;The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;Guangdong General Hospital;Sir run run shaw hospital Zhejiang University School of Medicine, Hangzhou, China;The First Affiliated Hospital of Zhengzhou University;Dongguan People's Hospital;Second Affiliated Hospital of Xi'an Jiaotong University;Beijing Chao Yang Hospital;Beijing Anzhen Hospital;Qingdao University	Recruiting	15 Years	70 Years	Both	90	Phase 2/Phase 3	China

88. 慢性血栓塞栓性肺高血圧症

臨床試験数 : 159 / 薬物数 : 118 - (DrugBank : 23) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 53

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01953965 (ClinicalTrials.gov)	September 2013	26/9/2013	Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance	Brigham and Women's Hospital	University of Pennsylvania;University of Maryland;Yale University	Terminated	18 Years	72 Years	Both	4	Phase 2	United States

先頭へ